|
|
 |
 |
| |
 Printable version |
New molecules for type 2 diabetes |
Sang Thrombose Vaisseaux. Volume 13, Number 2, 89-95, Février 2001, Mini-revues
|
 Résumé
Article gratuit
|
Author(s) : Jean-Frédéric Blicklé |
Summary : The development of new drugs with fewer side effects than the sulfonylureas and metformin and which could possibly delay the secondary failure of oral therapy, represents a major challenge when considering the dramatic increase of the prevalence of type 2 diabetes, particularly in the elderly.
Due to their fast and short insulin secretory effect, glinides offer a perfect flexibility of use, allow a good control of postprandial hyperglycaemia while decreasing the risk of hypoglycaemia later after the meals. Other insulin secreting agents are under evaluation, particularly some GLP-1 derivatives, which stimulate both insulin synthesis and secretion, but only in the presence of hyperglycaemia, and, on the other hand, also inhibit the secretion of glucagon and slow gastric emptying. Until they become available, rapid and longed-acting insulin analogues could take a place in the treatment of oral drugs failure. In the category of insulin sentitizing agents, thiazolidinediones or glitazones, still on the market in the US, exhibit a glucose lowering effect in monotherapy and in combination with sulfonylureas and metformin. Other PPAR-g and RXR agonists appear promising and will perhaps, in the future, avoid some side effects of glitazones. Finally, pharmacologic treatments of obesity could also contribute to the management of type 2 diabetes. |
Keywords : |
|
